Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
2Xc1a0FXM1TkWxXk
